Comparative Pharmacology
Head-to-head clinical analysis: CLADRIBINE versus FOLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLADRIBINE versus FOLEX.
CLADRIBINE vs FOLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Methotrexate, the active ingredient in FOLEX, is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with thymidylate and purine synthesis, leading to inhibition of DNA replication and cell proliferation.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
30 mg/m2 intravenously once weekly for 2 weeks followed by a 1-week rest period, or 5-10 mg/m2 intramuscularly or intravenously every 3-4 weeks. For rheumatoid arthritis, 7.5-15 mg orally once weekly.
None Documented
None Documented
Clinical Note
moderateCladribine + Digoxin
"Cladribine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCladribine + Digitoxin
"Cladribine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCladribine + Deslanoside
"Cladribine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCladribine + Acetyldigitoxin
"Cladribine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Terminal half-life: 3-10 hours (mean ~5 hours) for low-dose regimens; higher doses or renal impairment may prolong half-life up to 24 hours.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Primarily renal excretion of unchanged drug: ~80-90% within 24 hours. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent